Drug Discovery News

E.U. panel recommends Inlyta for adults with kidney cancer

Fri, 25 May 2012 15:28:07 +0000

E.U. regulators have recommended Pfizer's kidney cancer drug Inlyta be approved for use in patients who don't respond to other medications. Pfizer ($PFE) said the panel recommended approving the drug for use only in adults, reports CBS News. The FDA, in January, approved the twice-a-day cancer pill. That approval marks another win on the targeted-cancer-drug front for Pfizer, which last year nabbed an FDA OK for its non-small-cell lung cancer treatment Xalkori for a subset of patients whose tumors express ALK mutations. Pfizer also markets two other drugs for advanced kidney cancer, Sutent and Torisel. Inlyta joins a crowded market: According to the FDA, there have now been 7 drugs for kidney cancer approved in the U.S. since the agency's nod for sorafenib in 2005. Story | More

House could vote on FDA bill next week

Fri, 25 May 2012 14:58:36 +0000

It is now up to the House.

The Senate Thursday voted 96-1 vote in favor of re-authorization of PDUFA. It now goes to the House, whose own version to extend the user-fee act for another 5 years is similar to the Senate's bill, The Wall Street Journal reports.

The Senate version would put in place the long-discussed increases in fees from drug- and devicemakers to get faster reviews of their products, and loop in genericsmakers who previously were exempt from the fees. But the bill also gives the FDA new authorities. It will allow them tighter controls to regulate foreign drugmakers, a large concern in recent years in the face of tainted products from overseas. It would also give the agency leverage to inspect the manufacturing plants of foreign companies, or to block their products if they refuse. It also puts the responsibility on drug manufacturers to audit their suppliers to insure that their APIs meet U.S. standards.

The Senate bill also takes on the issue of drug shortages, setting out requirements for drugmakers to notify the FDA of potential drug shortages and for the agency to look for alternative sources of supply when they do. Shortages have gotten worse in recent years, and affected patients have been calling on members of Congress for help, points out The New York Times. The bill also looks to shorten review times for drugs in an effort to get potentially life-saving treatments to the market faster, a measure that is controversial because of the chance the risks will be overlooked in the process.

Financially, the Congressional Budget Office has said the bill could save Medicare and Medicaid more than $750 million over 10 years by getting lower-priced drugs to the market faster. It also projects collecting, over 5 years, $4.1 billion in fees for reviewing branded drugs, $1.6 billion for generics and $609 million for medical devices, the Times reports. It also would collect $128 million for less-costly versions of biosimilars.

The House may vote on its bill as early as next week.

- read the Wall Street Journal story
- here's The New York Times' take

EMA supports Pradaxa but seeks sharper warnings for bleeding

Fri, 25 May 2012 14:05:44 +0000

European regulators say the upside of blockbuster drug Pradaxa still outweighs its the risks of fatal bleeding, but they want some more labeling caveats for the blockbuster drug.

The European Medicines Agency, or EMA, today said its safety committee has kept a close eye on post-marketing data for the blood thinner. While bleeding is serious complication, "the frequency of occurrence of fatal bleedings with Pradaxa seen in post-marketing data was significantly lower than what was observed in the clinical trials," it reported. Its solution is clearer guidance to patients and doctors about its risks.

The anti-coagulant drug from Boehringer Ingelheim, is one of a new generation of rivals to warfarin, known by brand-name Coumadin, which dominated the market for 50 years but with a long list of shortcomings. Pradaxa this year hit the $1 billion sales range and helped the company report a big earnings increase.

But Pradaxa and its peers--Eliquis, from Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) and Xarelto from Johnson & Johnson ($JNJ)--have a significant drawback. While warfarin has an antidote--vitamin K--that can reverse its effects, Pradaxa and its new class of rivals do not. That fact has led to a number of cases of fatal bleeding, and some of those have lead to lawsuits from families of patients who claim the risks were not spelled out, reports The Houston Press.

The FDA has also been doing more investigation of these post-marketing events but has, so far, said Pradaxa's benefits outweigh its risks.

- here's the EMA statement
- check out the Dow Jones take
- read the Houston Press story

Takeda takes buying binge into Brazil with $265M Multilab deal

Fri, 25 May 2012 13:43:36 +0000

Takeda has a yen for emerging markets--billions of yen, actually. Just two weeks ago, the Japanese company said it would plow more money into fast-growth countries, and now it's announcing a $265 million deal in Brazil. The Sao Paulo-based Multilab will join Takeda's Brazilian unit, bringing its broad sales network--and a portfolio of branded generics and over-the-counter products.

"This acquisition significantly reinforces Takeda's position in Brazil, which is the world's sixth largest economy and the biggest in South America," emerging markets chief Jostein Davidsen said in a statement. "[T]he acquisition of Multilab is a clear signal of our intention to become a significant player both in Brazil and other high-growth markets."

The Multilab deal follows last year's $13.6 billion buyout of Switzerland's Nycomed, which came with significant sales--and a significant commercial network--in emerging eastern European markets. Takeda wants to beef up sales not only by taking advantage of Nycomed's commercial heft in those countries, but also by feeding Nycomed products through its own channels in other regions.

Multilab will allow it to do just that. The Brazilian company has a distribution network of regional wholesalers and independent pharmacies, particularly in "emerging" areas of the country, Takeda said. Together with its own urban-based distribution, those legacy Nycomed products will have plenty of territory to penetrate.

Overall, Takeda aims to grow emerging markets sales to 20% to 25% of its revenue, sales executive Frank Morich told Reuters. That's about twice as big as their current slice of the pie. "The key message we are sending with this deal is that we are really serious about globalization," Morich said. "We will continue to go after such opportunities as they arise."

Takeda and its Japanese rivals have been on something of a shopping spree. They've acquired drugmakers outside of Japan to diversify away from their home market. Lately, the strong yen has helped fuel more deals. On its own, Takeda has spent $15 billion on M&A over the last couple of years, Bloomberg points out. Just last month, it bought U.S.-based URL Pharma for access to its gout drug Colcrys, which brought in $430 million last year. That cash will help fill the gap now that generics are eroding sales of Takeda's top-selling diabetes drug Actos.

- get the release from Takeda
- read the Reuters story
- see the Bloomberg piece

Ranbaxy brings in U.S. consultants as part of consent decree

Fri, 25 May 2012 13:02:03 +0000

Following through on the extensive consent decree announced earlier this year between Ranbaxy Laboratories and the U.S. Department of Justice, the Indian generics company is bringing in a couple of hired guns to tell it what improvements are left to be made.

CEO Arun Sawhney says he expects the U.S. consultants' work at its manufacturing plants in India to be completed by the end of June, reports the Economic Times. The disclosure is a reminder that although the drugmaker is again shipping product to the U.S., it will continue to operate under much more stringent FDA oversight than other companies.

Ranbaxy reported a huge first quarter, in large part because its North American sales doubled during the period, to 20.93 billion rupees ($375 million). That was tied to getting an FDA sign-off to manufacture and sell in the U.S. its generic version of Lipitor, made at one of its major Indian plants.

But it still has a long way to work its way back into the good graces of the FDA. In 2008, regulators uncovered a list of issues, including faked drug quality data, and banned 30 products from the U.S. The blueprint for that journey is laid out in the 55-page consent decree. Among other things, Ranbaxy is required to hire data-integrity and manufacturing experts who will watch over its shoulder, make recommendations and take the issues up with the FDA. If anything slips by these controls, Ranbaxy must establish, and publicize, an anonymous disclosure program so employees can report "suspected violations."

- read the Economic Times story

FDA relies on health professionals, not recall, with Hospira overfills

Fri, 25 May 2012 01:25:09 +0000

The problems with overfilled Hospira Carpuject syringes is far more extensive than first suspected, but instead of ordering a recall, which would create some immediate shortages, the FDA is leaning on health professionals to make sure the drugs are administered correctly.

Hospira ($HSP) alerted the FDA in April and May of overfilled cartridges containing morphine and hydromorphine after receiving complaints from users. That led the company to investigate. The probe led to the determination that as many as 280 lots of 15 different Carpuject products might have been overfilled. The FDA says that some of them may contain more than twice the labeled dosage. The products include everything from the morphine products to naloxone hydrochloride which reverses the effects of opioids, to heparin and heparin lock, according to a list on the FDA website.

In an emailed statement to FiercePharmaManufacturing, Hospira spokesman Daniel Rosenberg said "the potential for overfill occurrence is low, but medication overfill has been reported." He said the company has worked closely with the FDA to determine the appropriate steps.

Since the number of cartridges that may be overfilled "appears to be low" and the risk of shortages if all the lots are pulled is significant--and since healthcare professionals have the expertise to check--the FDA decided on the alert instead of a recall, the agency says.

The recalls and alert come even as Hospira has been putting extra attention to quality control after the company had to make improvements at three plants to address manufacturing issues outlined in an FDA warning letter.

- read the FDA alert

While we are off for holiday weekend, cargo thieves are not

Thu, 24 May 2012 18:42:24 +0000

FiercePharma will not publish Monday because of the Memorial Day holiday, but remember, while most of us are taking a winding down, cargo thieves will be gearing up. The three-day Memorial Day weekend is one of the worst for cargo theft losses throughout the year, explains Dan Burges, senior director of intelligence for FreightWatch International.

Here is what he suggests:

For warehousing operations, ensure your security alarm systems are functioning properly. FreightWatch also recommends the following:

• Treat all alarm trouble signals as an intrusion alarm
• Do not rely on a backup (cellular/radio) system
• If primary alarm fails, assign security officer to patrol facility exterior or have a member of management remain at the facility

For in-transit operations, FreightWatch recommends drivers remain vigilant and maintain communication with their dispatch when stopped at high-risk areas such as truck stops and rest areas. Loads should not be dropped or left unattended for any reason.

Have good holiday, and you will receive your next issue of FiercePharma on Tuesday.

Another German drugmaker, Riemser Arzneimittel, on the block

Thu, 24 May 2012 16:06:50 +0000

There must be something up in Germany, because another drugmaker there is on the market.

Privately owned Riemser Arzneimittel AG, one of the largest pharma firms in eastern Germany, is in talks with a "selected group" of private equity firms and strategic investors, CEO Michael Mehler tells Bloomberg. Sources tell the publication that Warburg Pincus, Montagu Private Equity and Triton Advisers U.K. are among those sizing it up. They also suggest the price tag is about €300 million euros ($379 million).

The company is owned by the Braun family, GE Healthcare Financial Services ($GE) and TVM Capital, and it has about €115 million in revenues a year, selling oncology and dermatology products, among others, Bloomberg says.

One has to wonder if the news leaked out because the owners of another German drugmaker, Aenova, just announced they were shopping that company. It is owned by private equity firm Bridgepoint, which indicated it has a price tag in the same general range, more than €400 million, or about $510 million, Reuters reports. Aenova is the agglomeration of Swiss Caps, which made capsule-based supplements and drugs, and Dragenopharm, a German contract manufacturer of prescription drugs. Bridgepoint put the two together in 2008. Now, it has 9 locations in Switzerland, Germany, France, Romania and the U.S., and it employs about 1,600.

Bloomberg also pointed out earlier this week that Sweden's Meda AB, which last year got a look by Canada's Valeant Pharmaceuticals ($VRX), also looks to be a good buyout candidate.

- read the Bloomberg piece
- get more from Bloomberg
- check out the Reuters story

Sanofi eyes Chinese cancer market with early drug trial

Thu, 24 May 2012 15:58:05 +0000

Sanofi ($SNY) CEO Chris Viehbacher is betting that an experimental liver cancer drug could make big inroads in China. The company is going ahead with the first human trials of the drug next year. Report

FDA panel draws blood in Xarelto's bid for new use

Thu, 24 May 2012 15:36:22 +0000

Lesson from FDA's panel meeting on Xarelto: Beware of "missingness." After a spirited debate over some missing study data, the advisory committee refused to back a big new use for the blood thinner. Between absent data on about 1,000 patients who withdrew from the trial and worries about its bleeding risks, Xarelto's bid for an expanded market went down.

The 6-4 vote doesn't doom Johnson & Johnson's ($JNJ) quest to market Xarelto for patients with acute coronary syndrome. The agency could still approve the new use, though it does tend to follow committees' advice. Further clouding the picture, however, is the fact that internal FDA assessments mirrored the panel's split vote. One reviewer recommended the new indication, while another questioned that pesky missing data.

"Were there not questions about loss to follow-up and missing data, it would have been a yes," pharmacist Alan Coukell, who voted no, told Reuters. "I want to see better evidence that this strategy of adding [Xarelto] ... is robustly better for the patient," said Steven Nissen of the Cleveland Clinic, who also voted against the new use.

"We appreciate the thoroughness of the committee's review, and will ensure the questions raised today are addressed with the FDA," said Paul Burton, a VP at J&J's Janssen unit. Leerink Swann analyst Seamus Fernandez predicted that the panel vote would delay the new use by as much as a year, Bloomberg reported.

Getting an ACS indication would help fuel Xarelto in its race against two other warfarin-alternative drugs: Pradaxa, from Boehringer Ingelheim, and Eliquis, from Bristol-Myers Squibb ($BMY) and Pfizer ($PFE). Both Xarelto and Pradaxa are approved to prevent stroke in patients with atrial fibrillation, while Eliquis awaits the FDA nod for that use. Xarelto is the only one of the three up for ACS approval. In ACS, it would compete with AstraZeneca's ($AZN) Brilinta and Eli Lilly's ($LLY) Effient.

- see the J&J release
- read the Reuters article
- get more from Bloomberg
- check out the CardioBrief coverage

SD Life Sciences Roundup: Takeda Consolidates, Startups Raise Cash

Thu, 24 May 2012 14:38:04 +0000

Bruce V. Bigelow

It’s been a busy week for startup funding, with Obalon Therapeutics, Aperio Technologies, Topera, and Ivera Medical closing on financing deals. We’ve also got drug development news from Ocera Therapeutics and MediciNova.

—Japan’s Takeda Pharmaceutical said it’s closing its center of excellence in South San Francisco, which has been focused on developing early stage antibody drugs, and consolidating its operations, now known as Takeda California, in San Diego. The company’s San Diego center of excellence, which is focused on structure-based drug discovery, has about 170 employees, according to a report by Gary Robbins of U-T San Diego. Keith Wilson, president and chief science officer of Takeda California, told the U-T that Takeda plans to add about 30 positions in San Diego by the end of the year.

—San Diego-based Qualcomm’s wireless health subsidiary, Qualcomm Life, named 25 members to an advisory council to help the business address key industry issues. The list includes Kleiner Perkins partner Brook Byers, X Prize founder Peter Diamandis, inventor Dean Kamen, Diego Miralles of Janssen Healthcare Innovation, Eric Topol of the Scripps Translational Science Institute, Psilos Ventures partner Lisa Suennen, and Larry Smarr, founding director of the California Institute for Telecommunications & Information Technology (Calit2).

—San Diego’s MediciNova (NASDAQ: MNOV) said its experimental asthma drug failed to meet the main goal of a second mid-stage trial. The drug developer said patients treated with its leading drug candidate, bedoradrine sulfate, showed significant improvement in other ways, but a sell off on Wall Street sent shares of MediciNova down by … Next Page »

Comments | Reprints | Share:

The 2012 New York ASCO Checklist

Thu, 24 May 2012 13:05:22 +0000

Arlene Weintraub

On June 1, cancer scientists and drugmakers will flock to Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO). The gathering is so prominent that many pharmaceutical companies hold off on releasing data from their clinical trials until the conference. This explains why ASCO is as important to Wall Street folks as it is to the oncology community: Any company that makes a splash at ASCO is likely to see its stock boom.

Here are some of the publicly held NYC-area companies that will be presenting news on their cancer compounds at ASCO.

Bristol-Myers Squibb (NYSE: BMY)

Bristol-Myers is planning ten oral presentations on its cancer pipeline at ASCO, but investors will likely zero in on BMS-936558—a promising drug candidate in a class called anti-PD-1. The company is testing the drug in a range of cancers and will be presenting data from clinical trials in advanced non-small-cell lung cancer, metastatic melanoma, and renal cell cancer. The abstracts of the trials have already generated some buzz: In lung cancer, for example, the drug elicited a response rate of 19 to 28 percent, which is considerable better than the 8 to 11 percent rate typical of existing therapies.

Celgene (NASDAQ: CELG)

The drug to watch from Celgene is pomalidomide, which the company recently submitted to the FDA for approval in the treatment of multiple myeloma. The drug is similar to Celgene’s blockbuster lenalidomide (Revlimid) in that it prompts the patient’s immune system to attack cancer cells. It also blocks the growth of new blood vessels, which keeps vital nutrients from getting to myeloma cells. The company will present data from trials of the drug in combination with other treatments.

Johnson & Johnson (NYSE: JNJ)

J&J’s abiraterone acetate (Zytiga) is already approved to treat prostate cancer. Still, the company will be presenting several sets of data, including a trial on the survival benefit offered by the drug and an analysis of its cost effectiveness—a measure that’s increasingly important to managed care companies and other insurers who are looking to slash expenses.

Merck (NYSE: MRK)

Merck will be presenting early-stage data on two of its emerging oncology compounds. MK-3475 is being tested in patients with advanced solid tumors. MK-2206 is being tried in breast cancer, advanced solid tumors, and lung cancer.

Progenics (NASDAQ: PGNX)

This is one of the many companies working on a hot new class of compounds called antibody drug conjugates (ADCs). These drugs are akin to smart bombs, because they are designed to home in on cancer cells and deliver their payload of tumor-killing medicines directly to them, while sparing normal tissue. Progenics is testing its ADC in prostate cancer, and it will be presenting data from an early human trial at ASCO.

Pfizer (NYSE: PFE)

This NYC-based drug giant is presenting a whopping 100 abstracts at ASCO. Two drugs to watch are dacomitinib in lung cancer and inotuzumab ozogamicin—another ADC–in acute lymphocytic leukemia.

Regeneron (NASDAQ: REGN)

Regeneron is planning several presentations on its cancer compound, aflibercept, which works by binding two proteins that are involved in abnormal blood-vessel growth. The drug, a version of which is already approved to treat the eye disease macular degeneration, is being tested in a range of cancers, including colon cancer and lung cancer.

Cyclacel (NASDAQ: CYCC)

This company has been struggling to advance its leukemia drug, sapacitabine. It will present early data from trials of the same drug in another type of blood cancer, myelodysplastic syndrome, as well as in solid tumors.

Comments | Reprints | Share:

MediciNova Misses Primary Goal in Mid-Stage Trial of IV Asthma Drug

Wed, 23 May 2012 23:58:24 +0000

Bruce V. Bigelow

It was clear that San Diego’s MediciNova (NASDAQ: MNOV) had a lot riding on the outcome of a mid-stage trial of the company’s lead drug candidate, bedoradrine sulfate. As I reported recently, MediciNova has been developing the compound to treat acute asthma attacks that are not responsive to standard therapy.

So shareholders registered their disappointment in preliminary results that MediciNova released today after regular Nasdaq trading ended—sending shares of MediciNova down by roughly 50 percent in after hours trading. Less than two hours after the news hit the wires, MediciNova’s shares were trading around $1.40, after falling by $1.35, or 49 percent, from $2.75 a share.

Many investors probably didn’t read much beyond the first sentence, which says the Phase 2b trial “did not statistically meet the primary endpoint, improvement in forced expiratory volume (FEV1),” compared to a placebo. In other words, patients who got the drug did no better in exhaling for one second than patients who got a placebo. Yet bedoradrine showed a significant improvement in other ways over the placebo group as well as patients who only received the current standard of care. MediciNova says its drug also reduced hospital admissions in acute asthma cases, and no significant safety or tolerability issues were seen.

Shareholders were likely expecting to see “home-run data,” MediciNova CEO Yuichi Iwaki told me by telephone late this afternoon. “We put the fact that we did not meet primary end point at the beginning,” he said. “If you read through everything, we clearly indicate that the trial was positive, and we’re ready to move onto Phase 3.”

Iwaki says the failure to meet the primary goal of the mid-stage trial was probably due to protocols that called for giving patients a two-hour intravenous infusion, which he says were based on an outdated trial design. The company has maintained that its drug poses a key advantage over the current standard of care in U.S. emergency rooms, which typically use an inhaled drug like albuterol, because constricted airways limit how much aerosol can be absorbed. As an IV drug, doctors have a better understanding of how much bedoradrine a patient has absorbed.

In a statement from MediciNova, Iwaki says, “We believe certain variables, such as administration of off-protocol therapies, especially in the standard-of-care alone group (placebo arm) and somewhat higher-than-anticipated variability in measuring FEV1 values limited the [bedoradrine] outcomes. Our goal is to control for these variables going forward, enabling us to run a successful Phase 3 program. Accordingly, we have filed our End-of-Phase 2 meeting request with the Division of Pulmonary, Allergy, and Rheumatology Products at FDA.”

Comments | Reprints | Share:

Antibody-Coated Particles Slow Tumor Growth

nobody@acs.org("Aaron A. Rowe") — Tue, 22 May 2012 18:13:00 +0000

Drug Delivery: Polymer nanoparticles help antibodies target an extracellular matrix enzyme

Faults Found In India’s Drug Agency

nobody@acs.org("Jean-François Tremblay") — Mon, 21 May 2012 16:47:13 +0000

Pharmaceuticals: Parliamentary committee identifies weaknesses and seeks change of focus, better support

Agent Boosts Cancer Cells’ Vulnerability

nobody@acs.org("Stu Borman") — Mon, 14 May 2012 05:00:00 +0000

Drug Discovery: Researchers use the power of multivalency to design a better cancer trap

A Timely Release Of Gene-Silencing Molecules

nobody@acs.org("Erika Gebel") — Mon, 07 May 2012 18:37:54 +0000

Drug Delivery: Polymer particles deliver nucleic acids with low toxicity

Teaching Old Drugs New Tricks

nobody@acs.org("Susan R. Morrissey") — Mon, 07 May 2012 05:00:24 +0000

Research: NIH program aims to find new uses for promising compounds shelved by pharma

Pfizer Settles Celebrex Lawsuit

nobody@acs.org("Rick Mullin") — Fri, 04 May 2012 17:00:00 +0000

Intellectual Property: Drug firm logs a $450 million charge

AstraZeneca To Buy Ardea

nobody@acs.org("Ann M. Thayer") — Mon, 30 Apr 2012 05:00:22 +0000

Pharmaceuticals: Small-molecule drug firm will bring a late-stage gout treatment

Simple Probe Allows Drug Candidate Screening Without Labels

nobody@acs.org("Erika Gebel") — Fri, 27 Apr 2012 12:37:26 +0000

Drug Discovery: A small molecule fluoresces only when dislodged from a protein target by a drug molecule

AstraZeneca To Buy Ardea

nobody@acs.org("Ann M. Thayer") — Mon, 23 Apr 2012 21:21:00 +0000

Pharmaceuticals: Small-molecule drug firm will bring a late-stage gout treatment

Merck Licenses Endocyte Drug

nobody@acs.org("Lisa M. Jarvis") — Mon, 16 Apr 2012 20:02:59 +0000

Pharmaceuticals: Late-stage drug and diagnostic could be useful in treating many cancers

Red Blood Cells Release Cargo On Demand

nobody@acs.org("Prachi Patel") — Mon, 16 Apr 2012 16:52:00 +0000

Drug Delivery: By coating the cells with gold nanoparticles, researchers hope to enable drug delivery to tumors

Amgen Will Buy Peptide Firm Kai

nobody@acs.org("Lisa M. Jarvis") — Mon, 16 Apr 2012 05:00:31 +0000

Biopharmaceuticals: Acquisition adds a late-stage therapeutic to the biotech’s pipeline

Curbing Antibiotic Use

nobody@acs.org("Britt E. Erickson") — Mon, 16 Apr 2012 05:00:30 +0000

Health: FDA calls on drug industry to phase out nonmedical uses in animals

Protecting Antibiotics

nobody@acs.org("Britt E. Erickson") — Thu, 12 Apr 2012 23:26:00 +0000

Health: FDA calls on drug industry to phase out nonmedical uses in animals

New Firm Targets Drug Conjugates

nobody@acs.org("Ann M. Thayer") — Wed, 11 Apr 2012 23:26:00 +0000

Partners invest in start-up to develop antibody drug conjugates for oncology targets

Covalent Ties Reversed

nobody@acs.org("Celia Henry Arnaud") — Mon, 09 Apr 2012 05:00:00 +0000

Drug Design: Dual activation groups lead to rapidly reversible covalent kinase inhibitor

Proteins In Small Packages

nobody@acs.org("Erika Gebel") — Tue, 03 Apr 2012 15:11:00 +0000

Nanotechnology: Lipid vesicles synthesize proteins on command for targeted drug delivery

Graphene Envelops Nanoparticles

nobody@acs.org("Prachi Patel") — Mon, 02 Apr 2012 16:03:00 +0000

Nanoparticle Delivery: Simple method yields tiny graphene packets that could hold drugs or imaging agents

Chicken Feathers Carry Drugs

nobody@acs.org("Naomi Lubick") — Thu, 29 Mar 2012 17:03:47 +0000

Pharmaceuticals In The Environment: Agricultural feed and fertilizer made from chicken feathers may transfer drugs to the environment

Death To Cancer

nobody@acs.org("Erika Gebel") — Mon, 26 Mar 2012 16:07:00 +0000

Drug Development: Researchers harness the natural cell-death pathway to destroy cancer cells and test an experimental drug in an early stage clinical trial

Merck’s New Model For Collaboration

nobody@acs.org("Lisa M. Jarvis") — Mon, 19 Mar 2012 05:00:19 +0000

Drug Discovery: Pact with Scripps researcher will draw ideas from academia

India Forces Drug License

nobody@acs.org("Jean-François Tremblay") — Mon, 19 Mar 2012 05:00:12 +0000

Drug Pricing: Official rules that too few patients can afford a Bayer medication

Researchers Tightly Control Gold Nanoparticle Size

nobody@acs.org("Aaron A. Rowe") — Fri, 16 Mar 2012 05:00:00 +0000

Drug Delivery: Spheres could carry cancer drugs and reduce chemotherapy’s side effects

Merck’s New Model For Collaboration

nobody@acs.org("Lisa M. Jarvis") — Thu, 15 Mar 2012 21:33:00 +0000

Drug Discovery: Pact with Scripps researcher will draw ideas from academia

Nanoparticles Release Drugs On Demand

nobody@acs.org("Jeffrey M. Perkel") — Tue, 13 Mar 2012 20:42:51 +0000

Drug delivery: Zapped with ultraviolet light, polymer particles shrink

New Sensor Listens To Drug Molecules

nobody@acs.org("Erika Gebel") — Mon, 12 Mar 2012 16:27:16 +0000

Pharmaceutical Analysis: Vibrations of a quartz crystal measure properties that could make or break drug candidates

Graphene Targets Mouse Tumor

nobody@acs.org("Melissae Fellet") — Tue, 28 Feb 2012 16:29:00 +0000

Nanomedicine: The carbon material could image tumors or deliver anti-cancer drugs, possibly with low toxicity